Zhao Hongyu, Shui Bing, Zhao Qian, Hu Zhansheng, Shu Qiang, Su Mingming, Zhang Yingjie, Ni Yan
Central Laboratory, Beijing Obstetrics and Gynecology Hospital Capital Medical University, Capital Medical University, Beijing 100026, People's Republic of China; Department of Cardiovasology, First Affiliated Hospital, Jinzhou Medical University, Jinzhou, Liaoning Province, People's Republic of China.
Department of Clinical Laboratory, First Affiliated Hospital, Jinzhou Medical University, Jinzhou, Liaoning Province, People's Republic of China.
Can J Cardiol. 2021 Feb;37(2):300-309. doi: 10.1016/j.cjca.2020.03.024. Epub 2020 Mar 28.
Heart failure with midrange ejection fraction (HFmrEF) has been recently acknowledged as a separate phenotype, but metabolomics evaluation of this subtype remains largely unexamined.
A quantitative metabolomics study on amino acids and acylcarnitines was performed to characterize different states of heart failure (HF) in 628 participants. Both multivariate orthogonal partial least squares- discriminant analysis and univariate Mann-Whitney U test were used to explore reliable metabolic profiles associated with different HF states. The resulting metabolites were further refined to obtain diagnostic metabolite scores (DMSs) with the use of ordinal logistic regression. Lasso-penalized regression was applied to produce a survival-associated prognostic metabolite score (PMS). The Cox proportional hazards model, Kaplan-Meier curves, and time-dependent receiver operating characteristics were used for a comprehensive assessment of prognostic value using PMS versus traditional clinical biomarkers.
The optimized models identified a panel of 15 differential metabolites that were shared across different HF states, whereas some metabolites were associated with a specific state. PMS consisting of 9 metabolites demonstrated an appreciably better prognostic value (hazard ratio [HR] 1.62, 95% confidence interval [CI] 1.25-2.1) vs the natural logarithm of N-terminal pro-B-type natriuretic peptide (Ln[NT-proBNP]; HR 1.23, 95% CI 0.94-1.61; P < 0.001). The overall area under the receiver operating characteristic curve value of PMS was superior to that of Ln(NT-proBNP) in risk prediction for patients with HFmrEF and HF with reduced ejection fraction (HFrEF) subtypes (P < 0.001).
Targeted metabolomics has provided a novel understanding of the molecular mechanism underlying HF. Both DMS and PMS clearly demonstrated HFmrEF as a distinct phenotype between a mild HF with preserved ejection fraction state and a severe HFrEF state. PMS exhibited superior prognostic value than Ln(NT-proBNP). Further investigation is needed with independent large-scale validation.
射血分数中等范围的心力衰竭(HFmrEF)最近被确认为一种独立的表型,但对该亚型的代谢组学评估在很大程度上仍未得到研究。
对628名参与者进行了一项关于氨基酸和酰基肉碱的定量代谢组学研究,以表征心力衰竭(HF)的不同状态。多变量正交偏最小二乘判别分析和单变量曼-惠特尼U检验均用于探索与不同HF状态相关的可靠代谢谱。使用有序逻辑回归对所得代谢物进行进一步优化,以获得诊断代谢物评分(DMS)。应用套索惩罚回归生成与生存相关的预后代谢物评分(PMS)。使用Cox比例风险模型、Kaplan-Meier曲线和时间依赖性受试者工作特征,对PMS与传统临床生物标志物的预后价值进行综合评估。
优化模型确定了一组15种差异代谢物,这些代谢物在不同HF状态中均有出现,而有些代谢物与特定状态相关。由9种代谢物组成的PMS显示出明显更好的预后价值(风险比[HR]1.62,95%置信区间[CI]1.25 - 2.1),相比N末端B型利钠肽原的自然对数(Ln[NT-proBNP];HR 1.23,95% CI 0.94 - 1.61;P < 0.001)。在HFmrEF和射血分数降低的心力衰竭(HFrEF)亚型患者的风险预测中,PMS的受试者工作特征曲线下总面积优于Ln(NT-proBNP)(P < 0.001)。
靶向代谢组学为HF的分子机制提供了新的认识。DMS和PMS均清楚地表明HFmrEF是射血分数保留的轻度HF状态和严重HFrEF状态之间的一种独特表型。PMS表现出比Ln(NT-proBNP)更好的预后价值。需要进行独立的大规模验证进一步研究。